Developer docs
API playgroundTry for free, no card

Search company profiles

NVision Imaging Technologies

Full company profile

uuid0000i3b

Namestring
NVision Imaging Technologies
Legal namestring
NVision Imaging Technologies GmbH
Company typeenum
Private
Founded yearint
2016
Descriptiontext

NVision Imaging Technologies GmbH (operating as NVision Quantum Technologies) is a German quantum-technology company founded in 2016 and headquartered in Ulm. It has built two product platforms from a common underlying capability in engineered molecular quantum systems. POLARIS is a quantum-enhanced MRI device that uses parahydrogen-induced polarization to boost the magnetic signal of engineered sugar molecules by over 10,000x, enabling real-time metabolic imaging of tumors without radioactive radiation. PIQC is the company's molecular quantum computing platform, in which engineered organic carbene molecules act as long-lived qubits with intrinsic photonic interfaces, with the company having demonstrated first optical control of quantum information in a single molecule and spin lifetimes exceeding 2 milliseconds at 4 kelvins.

The company's commercial motion is enterprise and research-focused: POLARIS is deployed at leading cancer research institutions (initial deployment at Memorial Sloan Kettering Cancer Center, with plans to reach 20 centers across the U.S., Europe, and Asia by year-end 2026), while PIQC is positioned for downstream applications in drug discovery for previously undruggable targets. Revenue today is a mix of grant income from European public funding sources (over EUR 35 million since 2022, including EUR 15 million from the European Investment Bank), emerging POLARIS hardware sales or leasing to research centers, and future potential licensing or royalty streams from quantum-computing-enabled drug discovery. A $55 million Series B in May 2026 led by Abbott, alongside Playground Global, b2venture, Entree Capital, Lauder, and Pathena, valued the company at over $250 million.

The company was co-founded by CEO Sella Brosh (former McKinsey senior engagement manager) and CTO Ilai Schwartz (PhD, Ulm University), together with scientific co-founders Prof. Martin Plenio (75,000+ citations, Alexander von Humboldt Professorship), Prof. Fedor Jelezko (Zeiss Research Award), and Prof. Alex Retzker, giving it deep ties to Ulm University, Hebrew University, and Aarhus University. The company is pursuing FDA approval for human clinical studies in 2027, indicating an intent to transition POLARIS from a research tool into a regulated clinical device.

Short descriptiontext

NVision Imaging Technologies develops quantum-enhanced MRI (POLARIS) and molecular quantum computing (PIQC) platforms based on engineered organic molecules. It serves leading cancer research institutions with metabolic imaging devices and targets drug discovery applications for previously undruggable targets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersUlm, Germany
HQ citystring
Ulm
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
quantum-enhanced MRI, hyperpolarized metabolic imaging, molecular quantum computing, cancer diagnostic technology, medical imaging hardware
Industry4 codes
PRIMARYHLAHABAC
Magnetic Resonance Imaging (MRI) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAGAHAF
Quantum Photonics & Quantum Imaging (Single-Photon, Lidar, Ghost Imaging)
SECONDARYHDAGAHAD
Quantum Magnetometry (SQUID/OPM/NV and related)
SECONDARYHDAHAAAH
Optoelectronics & Photonics (LED/Laser/Optical ICs)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Scientific Research and Development Services5417
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Laboratory Analytical Instruments3826
Product category
Quantum Medical Imaging Equipment
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1POLARIS Device Sales/Leasing
TypeHardware Sales
Description

NVision generates revenue through the deployment and sale of its POLARIS quantum-enhanced MRI device to cancer research institutions. The Polaris device is deployed at leading research centers, suggesting a hardware sales or leasing model for research institutions.

itnonline.com
2Quantum Computing Platform (PIQC)
TypeLicensing Royalties
Description

The company leverages its quantum computing breakthrough to design new drugs for previously undruggable targets, potentially opening future revenue streams through pharmaceutical partnerships and drug discovery collaborations.

forbes.com
3Research Grants and Public Funding
TypeManaged Services
Description

NVision receives significant public funding through European research consortiums, including grants from the European Investment Bank, Innovation Fund Denmark, and ERC Synergy Grants, supporting R&D across quantum-enhanced MRI and quantum computing.

ad-hoc-news.de
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NVision develops and manufactures the POLARIS quantum-enhanced MRI system, which uses parahydrogen-induced polarization to amplify the magnetic signal of engineered sugar molecules by over 10,000x, enabling real-time metabolic imaging of tumors for cancer diagnosis and treatment response monitoring. The company also develops PIQC, a molecular quantum computing platform based on engineered organic carbene molecules with photonic interfaces, positioned as the foundation for the world's first molecular quantum computer. POLARIS devices are sold or leased to leading cancer research institutions, with Memorial Sloan Kettering Cancer Center as the first deployment site.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Cancer treatment feedback cycle reduced from months to days
+4 more records
Product overview1 text field

NVision offers two main quantum technology platforms: POLARIS is a quantum-enhanced MRI system that boosts MRI signal sensitivity by over 10,000x through parahydrogen-induced polarization of engineered sugar molecules, enabling real-time metabolic imaging for cancer diagnosis and treatment monitoring. PIQC is a molecular quantum computing platform based on engineered organic molecules with long-lived qubits integrated natively on photonic chips, designed for scalability and forming the foundation for quantum computing applications. Both technologies leverage molecular quantum systems engineered at the molecular level, with POLARIS focused on quantum sensing for medical imaging and PIQC targeting quantum computing.

Product and service2 records
1POLARIS Quantum-Enhanced MRI
CategoryMedical Imaging Equipment / Quantum Diagnostics
Description

Quantum-enhanced MRI device that boosts the magnetic signal of engineered sugar molecules by over 10,000x using parahydrogen-induced polarization, making metabolic activity in cancer cells visible to MRI in real time without radioactive radiation. Targets cancer research institutions and oncology centers for tumor diagnosis, treatment response monitoring, and earlier cancer detection.

2PIQC (Photonic Integrated Quantum Computing) Platform
CategoryQuantum Computing Platform / Molecular Quantum Hardware
Description

The first quantum computing platform based on molecular quantum nodes native to photonic chips, where engineered organic molecules combine long-lived qubits with intrinsic photonic interfaces in a scalable architecture. Designed as the foundation for the world's first molecular quantum computer, with future applications in drug discovery for previously undruggable targets.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

NVision Imaging Technologies GmbH and Aarhus University were jointly awarded a €5.4 million (40m DKK) grant under Denmark's Grand Solutions in Quantum Technologies program for the MIRAQLE project. The project aims to advance clinical translation of quantum-enhanced MRI for early liver cancer diagnostics, leveraging NVision's POLARIS technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Memorial Sloan Kettering Cancer Center is using NVision's Polaris quantum-based hyperpolarized metabolic MRI device in oncological preclinical studies, marking the first deployment of the technology at a leading cancer research institution. This represents a key clinical validation partnership.

3SPINNING Project Consortium
Strategic tierNotableTypeStrategic or Co-development Partner
Description

NVision participates in the SPINNING project, a joint initiative developing a diamond spin-photon-based quantum computer demonstrator involving six universities, two non-profit research institutions, five industrial companies, and fourteen associated partners, coordinated by Fraunhofer IAF and funded by the German Federal Ministry of Education and Research.

spinning-quantencomputing.de
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the world's largest MRI system manufacturers, with a deep installed base in hospitals and research centers. Highly comparable to NVision as the dominant incumbent POLARIS would need to integrate alongside or differentiate from; also a likely strategic-partner or acquirer given NVision's Ulm/German footprint.

TypeBroad incumbent
Description

Global MRI incumbent with broad hospital distribution and a strategic focus on precision diagnostics. Directly comparable as a peer whose installed MRI base represents both the integration target for POLARIS and the primary competitive incumbent for any future quantum-enhanced MRI workflow.

TypeDirect peer
Description

Manufactures preclinical MRI and NMR systems including hyperpolarization instrumentation for research institutions. The closest direct comparable to NVision on the hyperpolarized-metabolic-imaging side, serving the same cancer-research buyer with adjacent technology.

TypeDirect peer
Description

Photonic quantum computing company pursuing fault-tolerant quantum systems and explicitly co-presented with NVision at quantum-industry events. The most directly comparable peer for NVision's PIQC platform given the shared photonic-chip architecture and similar technical ambition.

TypeDirect peer
Description

Photonic quantum computing company developing scalable, room-temperature quantum systems. Comparable to NVision on PIQC's photonic-chip architecture and on the strategy of building full-stack quantum hardware for both computing and sensing use cases.

TypeBroad incumbent
Description

One of the largest standalone quantum computing companies, combining trapped-ion hardware with a full software stack. Comparable to NVision as a peer targeting pharmaceutical and materials-science customers that overlap with NVision's stated drug-discovery use cases for PIQC.

7Magnetic Insight
TypeDirect peer
Description

Specializes in magnetic particle imaging and hyperpolarized contrast agents for preclinical research. Highly comparable to NVision's POLARIS business on the hyperpolarization-and-preclinical-oncology-imaging axis, serving the same cancer-research customer base.

TypeDirect peer
Description

Trapped-ion quantum computing company pursuing both general-purpose quantum advantage and pharma-relevant applications. Comparable to NVision on the quantum-computing side of PIQC, particularly for the drug-discovery-for-undruggable-targets value proposition.

TypeEmerging player
Description

Early-stage quantum algorithms company co-presented with NVision at industry events and focused on near-term quantum advantage for materials and chemistry. Comparable to NVision as a fellow emerging quantum-computing peer targeting pharmaceutical and chemistry applications.

TypeEmerging player
Description

Quantum sensing company using NV-center diamond technology for nanoscale imaging, with academic roots overlapping NVision's Ulm ecosystem. Comparable to NVision on the quantum-sensing and NV-center IP foundation underlying both POLARIS and PIQC.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds20 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NVision Imaging Technologies

Quantum Medical Imaging Equipmentnvision-imaging.com

NVision Imaging Technologies develops quantum-enhanced MRI (POLARIS) and molecular quantum computing (PIQC) platforms based on engineered organic molecules. It serves leading cancer research institutions with metabolic imaging devices and targets drug discovery applications for previously undruggable targets.

What NVision Imaging Technologies does

NVision Imaging Technologies GmbH (operating as NVision Quantum Technologies) is a German quantum-technology company founded in 2016 and headquartered in Ulm. It has built two product platforms from a common underlying capability in engineered molecular quantum systems. POLARIS is a quantum-enhanced MRI device that uses parahydrogen-induced polarization to boost the magnetic signal of engineered sugar molecules by over 10,000x, enabling real-time metabolic imaging of tumors without radioactive radiation. PIQC is the company's molecular quantum computing platform, in which engineered organic carbene molecules act as long-lived qubits with intrinsic photonic interfaces, with the company having demonstrated first optical control of quantum information in a single molecule and spin lifetimes exceeding 2 milliseconds at 4 kelvins.

The company's commercial motion is enterprise and research-focused: POLARIS is deployed at leading cancer research institutions (initial deployment at Memorial Sloan Kettering Cancer Center, with plans to reach 20 centers across the U.S., Europe, and Asia by year-end 2026), while PIQC is positioned for downstream applications in drug discovery for previously undruggable targets. Revenue today is a mix of grant income from European public funding sources (over EUR 35 million since 2022, including EUR 15 million from the European Investment Bank), emerging POLARIS hardware sales or leasing to research centers, and future potential licensing or royalty streams from quantum-computing-enabled drug discovery. A $55 million Series B in May 2026 led by Abbott, alongside Playground Global, b2venture, Entree Capital, Lauder, and Pathena, valued the company at over $250 million.

The company was co-founded by CEO Sella Brosh (former McKinsey senior engagement manager) and CTO Ilai Schwartz (PhD, Ulm University), together with scientific co-founders Prof. Martin Plenio (75,000+ citations, Alexander von Humboldt Professorship), Prof. Fedor Jelezko (Zeiss Research Award), and Prof. Alex Retzker, giving it deep ties to Ulm University, Hebrew University, and Aarhus University. The company is pursuing FDA approval for human clinical studies in 2027, indicating an intent to transition POLARIS from a research tool into a regulated clinical device.

NVision Imaging Technologies firmographics

Firmographics
Name
NVision Imaging Technologies
Legal name
NVision Imaging Technologies GmbH
Website
https://nvision-imaging.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
NVision Imaging Technologies develops quantum-enhanced MRI (POLARIS) and molecular quantum computing (PIQC) platforms based on engineered organic molecules. It serves leading cancer research institutions with metabolic imaging devices and targets drug discovery applications for previously undruggable targets.
Ownership category
akta.pro rank

NVision Imaging Technologies industry classification

Industry
Product category
Quantum Medical Imaging Equipment
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHABAC
Magnetic Resonance Imaging (MRI) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAGAHAF
Quantum Photonics & Quantum Imaging (Single-Photon, Lidar, Ghost Imaging)
SECONDARYHDAGAHAD
Quantum Magnetometry (SQUID/OPM/NV and related)
SECONDARYHDAHAAAH
Optoelectronics & Photonics (LED/Laser/Optical ICs)

Keywords

  • Quantum-enhanced MRI
  • Hyperpolarized metabolic imaging
  • Molecular quantum computing
  • Cancer diagnostic technology
  • Medical imaging hardware

Where NVision Imaging Technologies is headquartered

Location

Headquarters

HQ city
Ulm
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

NVision Imaging Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. POLARIS Device Sales/Leasing: NVision generates revenue through the deployment and sale of its POLARIS quantum-enhanced MRI device to cancer research institutions. The Polaris device is deployed at leading research centers, suggesting a hardware sales or leasing model for research institutions.
  2. Quantum Computing Platform (PIQC): The company leverages its quantum computing breakthrough to design new drugs for previously undruggable targets, potentially opening future revenue streams through pharmaceutical partnerships and drug discovery collaborations.
  3. Research Grants and Public Funding: NVision receives significant public funding through European research consortiums, including grants from the European Investment Bank, Innovation Fund Denmark, and ERC Synergy Grants, supporting R&D across quantum-enhanced MRI and quantum computing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

NVision Imaging Technologies product offering

Product offering

Core offering

NVision develops and manufactures the POLARIS quantum-enhanced MRI system, which uses parahydrogen-induced polarization to amplify the magnetic signal of engineered sugar molecules by over 10,000x, enabling real-time metabolic imaging of tumors for cancer diagnosis and treatment response monitoring. The company also develops PIQC, a molecular quantum computing platform based on engineered organic carbene molecules with photonic interfaces, positioned as the foundation for the world's first molecular quantum computer. POLARIS devices are sold or leased to leading cancer research institutions, with Memorial Sloan Kettering Cancer Center as the first deployment site.

Product overview

NVision offers two main quantum technology platforms: POLARIS is a quantum-enhanced MRI system that boosts MRI signal sensitivity by over 10,000x through parahydrogen-induced polarization of engineered sugar molecules, enabling real-time metabolic imaging for cancer diagnosis and treatment monitoring. PIQC is a molecular quantum computing platform based on engineered organic molecules with long-lived qubits integrated natively on photonic chips, designed for scalability and forming the foundation for quantum computing applications. Both technologies leverage molecular quantum systems engineered at the molecular level, with POLARIS focused on quantum sensing for medical imaging and PIQC targeting quantum computing.

Differentiator

Problem solved

Functional benefit

Products and services

  • POLARIS Quantum-Enhanced MRI Quantum-enhanced MRI device that boosts the magnetic signal of engineered sugar molecules by over 10,000x using parahydrogen-induced polarization, making metabolic activity in cancer cells visible to MRI in real time without radioactive radiation. Targets cancer research institutions and oncology centers for tumor diagnosis, treatment response monitoring, and earlier cancer detection.
  • PIQC (Photonic Integrated Quantum Computing) Platform The first quantum computing platform based on molecular quantum nodes native to photonic chips, where engineered organic molecules combine long-lived qubits with intrinsic photonic interfaces in a scalable architecture. Designed as the foundation for the world's first molecular quantum computer, with future applications in drug discovery for previously undruggable targets.

Quantifiable outcome

  • Cancer treatment feedback cycle reduced from months to days
  • +4 more outcomes

Companies that use NVision Imaging Technologies

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

NVision Imaging Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NVision Imaging Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and notable.

  • Aarhus UniversitycoreStrategic or Co-development Partner · 16 March 2026NVision Imaging Technologies GmbH and Aarhus University were jointly awarded a €5.4 million (40m DKK) grant under Denmark's Grand Solutions in Quantum Technologies program for the MIRAQLE project. The project aims to advance clinical translation of quantum-enhanced MRI for early liver cancer diagnostics, leveraging NVision's POLARIS technology.
  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development Partner · 11 December 2025Memorial Sloan Kettering Cancer Center is using NVision's Polaris quantum-based hyperpolarized metabolic MRI device in oncological preclinical studies, marking the first deployment of the technology at a leading cancer research institution. This represents a key clinical validation partnership.
  • SPINNING Project ConsortiumnotableStrategic or Co-development PartnerNVision participates in the SPINNING project, a joint initiative developing a diamond spin-photon-based quantum computer demonstrator involving six universities, two non-profit research institutions, five industrial companies, and fourteen associated partners, coordinated by Fraunhofer IAF and funded by the German Federal Ministry of Education and Research.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

NVision Imaging Technologies competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: One of the world's largest MRI system manufacturers, with a deep installed base in hospitals and research centers. Highly comparable to NVision as the dominant incumbent POLARIS would need to integrate alongside or differentiate from; also a likely strategic-partner or acquirer given NVision's Ulm/German footprint.
  • GE HealthCare: Global MRI incumbent with broad hospital distribution and a strategic focus on precision diagnostics. Directly comparable as a peer whose installed MRI base represents both the integration target for POLARIS and the primary competitive incumbent for any future quantum-enhanced MRI workflow.
  • Quantinuum: One of the largest standalone quantum computing companies, combining trapped-ion hardware with a full software stack. Comparable to NVision as a peer targeting pharmaceutical and materials-science customers that overlap with NVision's stated drug-discovery use cases for PIQC.

Direct peers

  • Bruker: Manufactures preclinical MRI and NMR systems including hyperpolarization instrumentation for research institutions. The closest direct comparable to NVision on the hyperpolarized-metabolic-imaging side, serving the same cancer-research buyer with adjacent technology.
  • PsiQuantum: Photonic quantum computing company pursuing fault-tolerant quantum systems and explicitly co-presented with NVision at quantum-industry events. The most directly comparable peer for NVision's PIQC platform given the shared photonic-chip architecture and similar technical ambition.
  • Xanadu Quantum Technologies: Photonic quantum computing company developing scalable, room-temperature quantum systems. Comparable to NVision on PIQC's photonic-chip architecture and on the strategy of building full-stack quantum hardware for both computing and sensing use cases.
  • Magnetic Insight: Specializes in magnetic particle imaging and hyperpolarized contrast agents for preclinical research. Highly comparable to NVision's POLARIS business on the hyperpolarization-and-preclinical-oncology-imaging axis, serving the same cancer-research customer base.
  • IonQ: Trapped-ion quantum computing company pursuing both general-purpose quantum advantage and pharma-relevant applications. Comparable to NVision on the quantum-computing side of PIQC, particularly for the drug-discovery-for-undruggable-targets value proposition.

Emerging players

  • Phasecraft: Early-stage quantum algorithms company co-presented with NVision at industry events and focused on near-term quantum advantage for materials and chemistry. Comparable to NVision as a fellow emerging quantum-computing peer targeting pharmaceutical and chemistry applications.
  • Qnami: Quantum sensing company using NV-center diamond technology for nanoscale imaging, with academic roots overlapping NVision's Ulm ecosystem. Comparable to NVision on the quantum-sensing and NV-center IP foundation underlying both POLARIS and PIQC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

NVision Imaging Technologies social profiles

Digital presence

NVision Imaging Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NVision Imaging Technologies leadership team

Management profile

Number of profiles

Profiles5 records

NVision Imaging Technologies funding detail

Funding detail

Funding overview

Funding rounds20 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NVision Imaging Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NVision Imaging Technologies

What does NVision Imaging Technologies do?

NVision develops and manufactures the POLARIS quantum-enhanced MRI system, which uses parahydrogen-induced polarization to amplify the magnetic signal of engineered sugar molecules by over 10,000x, enabling real-time metabolic imaging of tumors for cancer diagnosis and treatment response monitoring. The company also develops PIQC, a molecular quantum computing platform based on engineered organic carbene molecules with photonic interfaces, positioned as the foundation for the world's first molecular quantum computer. POLARIS devices are sold or leased to leading cancer research institutions, with Memorial Sloan Kettering Cancer Center as the first deployment site.

Is NVision Imaging Technologies a public or private company?

NVision Imaging Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was NVision Imaging Technologies founded?

NVision Imaging Technologies was founded in 2016. It employs 101 to 250 people.

Where is NVision Imaging Technologies based?

NVision Imaging Technologies is headquartered in Ulm, Germany, in the Europe region.

How does NVision Imaging Technologies make money?

Three revenue lines are on record. POLARIS Device Sales/Leasing is the primary driver. The others are quantum Computing Platform (PIQC) and research Grants and Public Funding.

Who are NVision Imaging Technologies's main competitors?

Broad incumbents on record are Siemens Healthineers, GE HealthCare and Quantinuum. Direct peers are Bruker, PsiQuantum, Xanadu Quantum Technologies, Magnetic Insight and IonQ. Emerging players are Phasecraft and Qnami.

Does NVision Imaging Technologies have an API?

No public API is recorded for NVision Imaging Technologies.

What industry is NVision Imaging Technologies in?

NVision Imaging Technologies's product category is Quantum Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAC, Magnetic Resonance Imaging (MRI) Systems, with a secondary code of HDAGAHAF, Quantum Photonics & Quantum Imaging (Single-Photon, Lidar, Ghost Imaging). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quantum ZeitgeistNVision designs molecule for individually addressable qubitNVision Quantum Technologies and Ulm University researchers designed a single molecule, di(-4-yl)carbene, that functions as a qubit individually connected by light. The molecule fluoresces only in three specific spin states, enabling individual qubit addressability and stability. This approach could enable scalable quantum computers by integrating into photonic integrated circuits.Quantum Zeitgeist3 ways NVision’s spin-photon interface May connect future Quantum unitsNVision Quantum Technologies designed a carbene molecule as a quantum bit, using a spin-photon interface to connect it to light. The team demonstrated control and readout of a single qubit, with the host crystal preserving quantum state. The design aims to scale to hundreds of thousands of qubits for complex simulations.Intelligent CIONVision molecular qubit breakthrough opens path to scalable quantum chips – Intelligent CIO EuropeNVision unveiled a molecular qubit architecture for semiconductor manufacturing, enabling individually addressable organic molecular spin-photon interfaces. The system tolerates 70% photon losses and targets prototype chips in Q4 2026, with a roadmap to 1,000 logical qubits by 2030.The Times of IndiaNVision develops quantum computing chips using smartphone display techniquesNVision published a Nature paper on Wednesday showing a new method to make quantum computing chips using techniques from smartphone displays. The company, which has raised over $155 million, found a molecule that can be deposited over conventional chips. It is partnering with HyperLight to build its first chips and plans to sell a rack-ready quantum computer.MarketScreenerGerman startup NVision shows new path to quantum computing chips in Nature paperGerman startup NVision published a Nature paper showing a method to make quantum computing chips using molecules from OLED displays. The company, which raised $120 million, developed a molecule that aligns electron spins, making sugars easier for MRI machines to see. NVision plans to partner with HyperLight to fabricate its first chips and build a full quantum computer.WhalesbookNVision Raises $155 Million To Develop OLED-Based Quantum ChipsGerman startup NVision raised $155 million, including Abbott Laboratories, to manufacture quantum chips using OLED-compatible materials. The firm plans vertical integration with HyperLight to build rack-ready systems, competing with IBM and Microsoft. Scaling production and maintaining performance remain key challenges.HpcwireNVision Reports Molecular Qubit Advance, Partners with HyperLight on Photonic Chips - HPCwireNVision announced a Nature publication on a single-molecule spin-photon interface and a partnership with HyperLight to integrate molecular qubits onto photonic chips. The carbene qubits operate at 2-4K and tolerate 70% photon loss, with first prototype chips expected in Q4 2026. The company targets 1,000 physical qubits and 1,000 logical qubits by 2030.Channel NewsAsiaGerman startup NVision shows new path to quantum computing chips in Nature paperGerman startup NVision published a Nature paper describing a new method to make quantum computing chips using molecules from OLED displays. The company, which raised $120 million, found a molecule that can be deposited on conventional chips. It plans to partner with HyperLight and build a full quantum computer.The future of tradingGerman startup NVision shows new path to quantum computing chips in Nature paperGerman startup NVision published a Nature paper describing a new method to make quantum computing chips using molecules from OLED displays. The company, which has raised over $155 million, is partnering with HyperLight to build its first chips and plans to fabricate a full quantum computer.ThequantuminsiderNVision and HyperLight Partner to Develop Photonic Quantum ChipsNVision published a Nature paper on individually addressable organic molecular spin-photon interfaces and partnered with HyperLight to integrate molecular qubits onto thin-film lithium niobate photonic integrated circuits. The collaboration targets on-chip performance demonstration by end of 2026, with a roadmap to 1,000 physical qubits and 1,000 logical qubits by 2030.